$GH News

Roth Capital Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $200

Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026

Guardant Health: Growth Remains Too Expensive, Reiterate Hold

Guardant Health (GH) After Shield And Reveal Data Is The Undervalued Story Still Intact

Is Guardant Health (GH) At A Turning Point After Its Patent Setback?

Is 99% Screening Adherence Altering The Investment Case For Guardant Health (GH)?

Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests

Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200

Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer

Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026

Guardant Health Receives European Approval Of Guardant360 CDx As Companion Diagnostic For AstraZeneca’s ETCAMAH

Barclays Maintains Overweight on Guardant Health, Raises Price Target to $220

Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma

Guardant Health Announces Results From Its COSMOS-MEL01 Trial Shows 81% Sensitivity For Distant Recurrence, 100% Post-Treatment Facility

Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $200

Guardant Health (GH) Lands First FDA Cleared Breast Cancer Liquid Biopsy Role

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

Guardant Health Nears Buy Point As Sales Outlook Brightens

Guardant Health, Inc. (GH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening